Stay updated with breaking news from Mark Wuttke. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Dopavision has announced positive topline results from a proof-of-concept trial of MyopiaX, a noninvasive photobiomodulation intervention designed to slow myopia progression in children.“The 6-month outcomes represent a significant step in the clinical development of MyopiaX,” Ian Flitcroft, PhD, FRCOphth, coordinating investigator of the MyopiaX-1 trial, said in a company press
Safe and Tolerable: MyopiaX-1 proof-of-concept clinical trial (NCT04967287) supports MyopiaX's excellent safety and tolerability profile with no untoward safety events. Novel Approach: Dopavision's
- MyopiaX-1 trial to generate first clinical evidence with MyopiaX®,a novel therapeutic approach to manage myopia progression
- MyopiaX-1 trial to generate first clinical evidence with MyopiaX®, a novel therapeutic approach to manage myopia progression- First data readout expected...
- Former Novartis ophthalmology program head significantly strengthens Dopavision´s management capabilities- Company recently initiated clinical trial of...